A spinoff from regenerative medicine company Pluri, which is also backed by Israeli food co Tnuva Group, Ever After Foods has exclusive licensing rights to Pluri’s IP around cultivated meat and fish, and has recently switched to a b2b model to give other companies access to its technology.
The latest capital injection—led by undisclosed “multinational companies” and Asian investors together with Tnuva and Pluri—will help the startup build its b2b strategy and provide bioreactors and edible scaffolds to third parties who can use their own cell lines or work with ones developed by Ever After Foods, CEO Eyal Rosenthal told AgFunderNews.
Source: Don’t write off cultivated meat just yet, says Ever After Foods